Clinical trials: Metastatic Kidney Carcinoma
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
Combination Chemotherapy Following Surgery in Treating Patients With Advanced Bladder Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00003133
- Testing
- filgrastim, cisplatin, doxorubicin hydrochloride
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma
ARID1A and/or KDM6A Mutation and CXCL13 Expression
This phase II trial studies the effect of nivolumab in urothelial cancer that has spread to other places in the body (metastatic), specifically in patients with aberrations in ARID1A gene (ARID1A mutation) and correlate with…
- Conditions
- Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma, Locally Advanced Ureter Urothelial Carcinoma, Locally Advanced Urethral Urothelial Carcinoma
- Trial name
- NCT04953104
- Testing
- Diagnostic Laboratory Biomarker Analysis, Nivolumab, Relatlimab
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- M.D. Anderson Cancer Center
Castration-Resistant Prostate Carcinoma, Metastatic Colorectal Carcinoma
Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME Trial
This trial compares cryoablation combined with stereotactic body radiation therapy to stereotactic body radiation therapy alone to see how well they work in treating patients with pain from cancer that has spread to the bones…
- Conditions
- Castration-Resistant Prostate Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Solid Neoplasm
- Trial name
- NCT04693377
- Testing
- Cryosurgery, Quality-of-Life Assessment, Stereotactic Body Radiation Therapy
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- M.D. Anderson Cancer Center
Carcinoma, Adenocarcinoma
Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney Cancer
To estimate the difference in efficacy and safety of bevacizumab and RAD001 compared to bevacizumab and interferon alfa-2a for first-line treatment of patients with metastatic carcinoma of the kidney.
- Conditions
- Carcinoma, Adenocarcinoma, Renal Cell, Nephroid Carcinoma
- Trial name
- NCT00719264
- Testing
- RAD001(everolimus), interferon alfa-2a, bevacizumab
- Where
- 109 sites in United States, Belgium and 19 more
- Volunteers
- 365 people
- Sponsor
- Novartis Pharmaceuticals
Clear Cell Papillary Renal Neoplasm, Collecting Duct Carcinoma
Pamiparib and Temozolomide for the Treatment of Hereditary Leiomyomatosis and Renal Cell Cancer
This phase II trial investigates how well pamiparib and temozolomide work in treating patients with hereditary leiomyomatosis and renal cell (kidney) cancer.
- Conditions
- Clear Cell Papillary Renal Neoplasm, Collecting Duct Carcinoma, Hereditary Leiomyomatosis and Renal Cell Carcinoma, Hereditary Papillary Renal Cell Carcinoma
- Trial name
- NCT04603365
- Testing
- Pamiparib, Temozolomide
- Sponsor
- Jonsson Comprehensive Cancer Center
Clear Cell Renal Cell Carcinoma (ccRCC), Melanoma
Study CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal Cell Carcinoma (ccRCC) and Non-Small Cell Lung Cancer (NSCLC)
This study is an open-label Phase 1/2 evaluation of CB-839 in combination with nivolumab in participants with clear cell renal cell carcinoma, melanoma, and non-small cell lung cancer.
- Conditions
- Clear Cell Renal Cell Carcinoma (ccRCC), Melanoma, Non-small Cell Lung Cancer (NSCLC)
- Trial name
- NCT02771626
- Testing
- CB-839, Nivolumab
- Where
- 17 sites in United States
- Volunteers
- 118 people
- Sponsor
- Calithera Biosciences, Inc
Adult Solid Neoplasm, Clear Cell Renal Cell Carcinoma
Sunitinib Malate in Treating Patients With Unresectable or Metastatic Kidney Cancer or Other Advanced Solid Tumors
This phase I trial is studying the side effects and best way to give sunitinib malate in treating patients with unresectable or metastatic kidney cancer or other advanced solid tumors.
- Conditions
- Adult Solid Neoplasm, Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Carcinoma, Stage III Renal Cell Cancer
- Trial name
- NCT00499135
- Testing
- Computed Tomography, Fluorothymidine F-18, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- National Cancer Institute (NCI)
Carcinoma, Renal Cell
SU011248 Versus Interferon-Alfa As First-Line Systemic Therapy For Patients With Metastatic Renal Cell Carcinoma
The purpose of this study is to test whether SU011248 has activity and is safe compared to interferon-alfa as first-line therapy in patients with metastatic renal cell carcinoma (RCC).
- Trial name
- NCT00083889
- Testing
- Interferon-alfa, SU011248
- Where
- 123 sites in United States, Australia and 9 more
- Volunteers
- 750 people
- Sponsor
- Pfizer
Urothelial Carcinoma
A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer
The main purpose of this study is to evaluate the safety and efficacy of the study drug ramucirumab in combination with docetaxel in participants with urothelial cancer who failed prior platinum-based therapy.
- Trial name
- RANGE (NCT02426125)
- Testing
- Ramucirumab, Docetaxel
- Where
- 141 sites in United States, Australia and 21 more
- Volunteers
- 530 people
- Sponsor
- Eli Lilly and Company
RCC, Metastatic Renal Cell Carcinoma
Nivolumab in mRCC Patients: Treg Function, T-cell Access and NK Interactions to Predict and Improve Efficacy
The project aims to identify Nivolumab predictive biomarkers in metastatic renal cancer patients through functional evaluation of peripheral Tregs and NKs.
- Trial name
- REVOLUTION (NCT03891485)
- Testing
- Immunological and tumour characterization
- Where
- Italy
- Volunteers
- 200 people
- Sponsor
- National Cancer Institute, Naples
Kidney Cancer
PEG-Interferon Alfa-2b, Sargramostim, and Thalidomide in Treating Patients With Metastatic Kidney Cancer
RATIONALE: PEG-interferon alfa-2b may interfere with the growth of tumor cells. Colony-stimulating factors such as sargramostim may increase the number of immune cells found in bone marrow or peripheral blood.
- Trial name
- NCT00090870
- Testing
- PEG-interferon alfa-2b, GM-CSF, thalidomide
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Medical University of South Carolina
Mucositis, Stomatitis
Folic Acid Supplement Versus Placebo for Treating Mucositis Adverse Events in Metastatic Renal Cell Carcinoma Patients Receiving Targeted Therapy
FASTERCC: Folic acid supplement versus placebo for treating mucositis adverse events in metastatic renal cell carcinoma patients receiving targeted therapy.
- Trial name
- DARENCA4 (NCT03581773)
- Testing
- Folic Acid
- Where
- 2 sites in Denmark
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Niels Fristrup
Clear Cell Renal Cell Carcinoma
Modulation of the Bone Immune Microenvironment Following Cabozantinib Treatment of Bone Metastatic Clear Cell Renal Cell Carcinoma: Proof of Concept Study
The goal of our study is to explore how treatments affect the bone immune microenvironment and determine the best treatment options for patients with metastatic kidney cancer to the bone.
- Trial name
- NCT07187869
- Testing
- Cabozantinib, Nivolumab
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- M.D. Anderson Cancer Center
Solid Tumor, Adult Central Nervous System Germ Cell Tumor
Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor
RATIONALE: Giving high-dose chemotherapy before an autologous stem cell transplant stops the growth of tumor cells by stopping them from dividing or killing them.
- Conditions
- Solid Tumor, Adult Central Nervous System Germ Cell Tumor, Adult Rhabdomyosarcoma, Childhood Central Nervous System Germ Cell Tumor
- Trial name
- NCT00638898
- Testing
- busulfan, melphalan, topotecan hydrochloride
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- City of Hope Medical Center
Urothelial Carcinoma, Bladder Cancer
Phase I Study With Sorafenib in Addition to Vinflunine in Metastatic Transitional Cell Carcinoma of the Urothelial Tract
This study aims to analyse the tolerability (side effects and safety) with standard treatment (Javlor®) with the addition of a second anti-tumour drug: sorafenib (Nexavar®).
- Conditions
- Urothelial Carcinoma, Bladder Cancer, Renal Pelvis Cancer, Ureter Cancer
- Trial name
- VINSOR (NCT01844947)
- Testing
- Vinflunine, Sorafenib
- Where
- 3 sites in Denmark, Sweden
- Volunteers
- 22 people
- Sponsor
- Dr Anders Ullén
Renal Cell Carcinoma
Phase Ib/II Trial of Interleukin-2 and PD-1 Checkpoint Inhibitor, Nivolumab In Metastatic Clear Cell Renal Cell Cancer
This will be a single arm, multi-site phase Ib/II clinical trial of standard doses of High Dose Interleukin-2 (HD IL2) (600,000 IU/kg/dose intravenously during two 5-day cycles 9 days apart) in IL-2 eligible clear cell metastatic…
- Trial name
- NCT02989714
- Testing
- Interleukin-2, Nivolumab
- Where
- 4 sites in United States
- Volunteers
- 13 people
- Sponsor
- University of Michigan Rogel Cancer Center
Renal Cell Cancer
Autologous Vaccination of Stage 4 Renal Cell Carcinoma Combined With Sunitinib
While different lines of evidence support the notion that renal cell cancer is amenable for immunologic vaccination, up to now the clinical benefit associated with vaccines has been limited.
- Trial name
- rcc (NCT00890110)
- Testing
- Autologous renal cell vaccine based on DNP modified cells
- Volunteers
- 13 people
- Sponsor
- Hadassah Medical Organization
Renal Cell Cancer Metastatic
CM082 Combined With Everolimus in Chinese Patients With Metastatic Renal Cell Carcinoma
This randomized, double blind, phase 2/3 study is aimed to evaluate the efficacy and safety of CM082 in combination with everolimus in Chinese patients with advanced renal cell carcinoma.
- Trial name
- NCT03095040
- Testing
- CM082 combined with everolimus, CM082, Everolimus
- Where
- China
- Volunteers
- 390 people
- Sponsor
- AnewPharma
Kidney Cancer
SWOG-9023, DNA Analysis of Tumor Tissue From Patients With Metastatic Kidney Cancer
RATIONALE: DNA analysis of tumor tissue may help doctors predict how well patients will respond to treatment. PURPOSE: This laboratory study is analyzing the DNA in tumor tissue from patients with metastatic kidney cancer.
- Trial name
- NCT00900042
- Testing
- DNA ploidy analysis, DNA stability analysis, chromosomal translocation analysis
- Volunteers
- 34 people
- Sponsor
- SWOG Cancer Research Network
Kidney Cancer Metastatic, Kidney Cancer
SBRT (Stereotactic Body Radiation Therapy) in Combination With Nivolumab/Ipilimumab in Renal Cell Carcinoma (RCC) / Kidney Cancer Patients
This is a multi-institution, single-arm phase II study to determine the safety and efficacy of SBRT (up to 2 metastatic sites preferentially lung, mediastinum or bone in combination of nivolumab and ipilimumab in patients with…
- Conditions
- Kidney Cancer Metastatic, Kidney Cancer, Kidney Cancer, Stage IV
- Trial name
- RADVAX (NCT03065179)
- Testing
- Nivolumab/Ipilimumab, SBRT
- Where
- 2 sites in United States
- Volunteers
- 29 people
- Sponsor
- University of Texas Southwestern Medical Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.